Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 7:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 132 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: No kidney transplant Clear all
Not listed No phase listed Observational Accepts healthy volunteers

In Vitro Study of the Effect of Gadolinium Contrast on Fibrocytes

NCT02512796
View directory record Official record
Conditions
Gadolinium Toxicity
Interventions
Gadolinium contrast dye
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 31, 2015 · Synced Sep 30, 2026, 7:23 PM EDT
Active, not recruiting Not applicable Interventional

Leveraging Technology to Improve Medication Adherence in Youth With Kidney or Liver Transplant

NCT05613010
View directory record Official record
Conditions
Transplant;Failure,Kidney, Transplant; Failure, Liver, Adherence, Medication, Adherence, Patient, Adherence, Treatment
Interventions
mHealth Messaging Intervention Group
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
13 Years to 25 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 30, 2026, 7:23 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety, Pharmacokinetics, and Preliminary Efficacy of Isatuximab in Patients Awaiting Kidney Transplantation

NCT04294459
View directory record Official record
Conditions
Immune System Disorder
Interventions
Isatuximab SAR650984, Acetaminophen (paracetamol) or equivalent, Ranitidine or equivalent, Diphenhydramine or equivalent, Methylprednisolone or equivalent, Montelukast or equivalent
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
4
States / cities
San Francisco, California • Rochester, Minnesota • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Sep 30, 2026, 7:23 PM EDT
Withdrawn Not applicable Interventional

Post Kidney Transplant Nocturnal Hypertension Prevalence and Management Study

NCT01120613
View directory record Official record
Conditions
Hypertension
Interventions
Chronotherapy
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Great Neck, New York
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Sep 30, 2026, 7:23 PM EDT
Completed Not applicable Interventional Results available

Medication Adherence in Kidney Transplant Recipients Using Automated Reminders and Provider Notification

NCT01541384
View directory record Official record
Conditions
Medication Adherence
Interventions
Vitality GlowCaps
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 11, 2017 · Synced Sep 30, 2026, 7:23 PM EDT
Withdrawn No phase listed Observational

Hybrid Closed-Loop Insulin Delivery System in Type 1 Diabetes Candidates for a Living Donor Kidney Transplant

NCT03494010
View directory record Official record
Conditions
Diabetes, Type 1
Interventions
Observation
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Sep 30, 2026, 7:23 PM EDT
Completed No phase listed Observational

Teen Adherence in KidnEy Transplant, Improving Tracking To Optimize Outcomes (Stage 1)

NCT02910661
View directory record Official record
Conditions
Medication Adherence
Interventions
Focus Group
Other
Lead sponsor
Beth Foster
Other
Eligibility
12 Years to 70 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
4
States / cities
St Louis, Missouri • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2017 · Synced Sep 30, 2026, 7:23 PM EDT
Completed Not applicable Interventional

Chronotherapy Versus Conventional BP Control to Correct Abnormal Circadian BP Pattern in Kidney Transplant Recipients

NCT01093703
View directory record Official record
Conditions
Blood Pressure Control, Kidney Transplant Recipient
Interventions
Medication Adjustment
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Sep 30, 2026, 7:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Reducing Disparities in Access to kidNey Transplantation (RaDIANT) Community Study

NCT02092727
View directory record Official record
Conditions
Kidney Disease
Interventions
Behavioral Interventions for Dialysis Facilities
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years to 69 Years
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Sep 30, 2026, 7:23 PM EDT
Completed Not applicable Interventional

Network Interventions to Reduce Disparities in Living Kidney Donation

NCT05255757
View directory record Official record
Conditions
End-stage Renal Disease
Interventions
Script Intervention, Search Intervention
Behavioral
Lead sponsor
Penn State University
Other
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Birmingham, Alabama • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 24, 2024 · Synced Sep 30, 2026, 7:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Increasing Donor Designation Rates in Teenagers: Effectiveness of a Driver's Education Intervention

NCT03013816
View directory record Official record
Conditions
Organ Donor Registration, Organ Donation Education
Interventions
Organ Donation Education: Testimonial Messaging, Organ Donation Education: Informational Messaging, Organ Donation Education: Blended Messaging
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
Not listed
Enrollment
611 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 28, 2019 · Synced Sep 30, 2026, 7:23 PM EDT
Completed Phase 2 Interventional Results available

Regimen Optimization Study

NCT02137239
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Thymoglobulin, Belatacept, mycophenolate mofetil(MMF), Corticosteroids, Everolimus(EVL), Tacrolimus(TAC)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
17
States / cities
San Diego, California • San Francisco, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Sep 30, 2026, 7:23 PM EDT
Active, not recruiting Not applicable Interventional

Screening for Asymptomatic Coronary Artery Disease in Kidney Transplant Candidates

NCT03674307
View directory record Official record
Conditions
Cardiovascular Diseases, End Stage Renal Disease, Kidney Transplantation, Dialysis Related Complication
Interventions
No screening, Regular Screening
Other
Lead sponsor
University of British Columbia
Other
Eligibility
18 Years and older
Enrollment
3,306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
2
States / cities
Tucson, Arizona • Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 30, 2026, 7:23 PM EDT
Completed Not applicable Interventional

Examining the Use of a Novel Immersive Motion Tracking Upper Extremity Exercise Program for Acute Hospitalized Patients

NCT06222554
View directory record Official record
Conditions
Kidney Transplant, Liver Transplant
Interventions
MoveMend Health
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Sep 30, 2026, 7:23 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Angiotensin II in Liver Transplantation

NCT04901169
View directory record Official record
Conditions
Liver Transplant; Complications, Vasoplegia
Interventions
Angiotensin II, Saline
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Sep 30, 2026, 7:23 PM EDT
Not listed Phase 1 Interventional

Combined Blood Stem Cell and Kidney Transplant of One Haplotype Match Living Donor Pairs.

NCT01165762
View directory record Official record
Conditions
ESRD
Interventions
Immune Tolerance
Drug
Lead sponsor
Everett Meyer
Other
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2025
U.S. locations
2
States / cities
Stanford, California • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Sep 30, 2026, 7:23 PM EDT
Recruiting Phase 2 Interventional

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

NCT06859424
View directory record Official record
Conditions
AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome), CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia), Prolymphocyctic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasm (MPN), Lymphoma, Myelofibrosis
Interventions
Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C, Conditioning Regimen D, Conditioning Regimen E, Hematopoietic Cell Transplantation, PTCy (50 mg/kg D3, D4), PTCy (25 mg/kg D3, D4), Post-transplant Tacrolimus, Post-transplant Mycophenolate mofetil, Post-transplant Abatacept, Post-transplant Ruxolitinib, Supportive Care: Growth Factors, Supportive Care: Blood Products, Supportive Care: Infection Prophylaxis, Supportive Care: Intravenous immune globulin (IVIG), Supportive Care: Seizure prophylaxis, Supportive Care: Monitoring and management of CRS, Supportive Care: Prophylaxis against infections, Supportive Care: Prophylaxis against infections, Supportive Care: Lipid elevations, Study treatment compliance, Prohibited Concomitant Therapy, Permitted Concomitant Therapy
Drug · Procedure · Other
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
18 Years to 66 Years
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Sep 30, 2026, 7:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

HLA-Identical Sibling Renal Transplant Tolerance

NCT00619528
View directory record Official record
Conditions
Immunosuppression, Kidney Transplantation, Graft Rejection
Interventions
Infusion of Donor Hematopoietic Stem Cells and Campath-1H
Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Sep 30, 2026, 7:23 PM EDT
Recruiting No phase listed Observational

An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive a Kidney Transplant

NCT05106387
View directory record Official record
Conditions
Chronic Kidney Disease (CKD)
Interventions
Noninterventional
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
9
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Sep 30, 2026, 7:23 PM EDT
Completed Not applicable Interventional Results available

The Effect of Rituximab on the Development of Anti-Donor Antibodies

NCT00695097
View directory record Official record
Conditions
Renal Transplant Rejection
Interventions
Rituximab, No Rituximab
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
2
States / cities
Birmingham, Alabama • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 26, 2014 · Synced Sep 30, 2026, 7:23 PM EDT
Completed No phase listed Observational

Evaluating Nulojix (Belatacept) Long-Term Safety in Transplant

NCT01386359
View directory record Official record
Conditions
Kidney Transplantation
Interventions
No Intervention
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
914 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
36
States / cities
Tucson, Arizona • Los Angeles, California • San Diego, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Sep 30, 2026, 7:23 PM EDT
Completed Phase 2 Interventional

Allo HSCT Using RIC for Hematological Diseases

NCT02661035
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Plasma Cell Leukemia, Myelodysplastic Syndromes, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, B-Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia, Lymphoblastic Lymphoma, Burkitt's Lymphoma, Non-Hodgkin's Lymphoma, Multiple Myeloma, Myeloproliferative Syndromes, Hematological Diseases
Interventions
Allopurinol, Fludarabine, Cyclophosphamide, ATG, TBI, Tacrolimus, MMF, Peripheral Blood Stem Cells, Related or Unrelated Bone Marrow Cells
Drug · Radiation · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 75 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Sep 30, 2026, 7:23 PM EDT
Completed No phase listed Observational

Assess Burden of Disease Among Kidney Transplant Recipients With Chronic Active Antibody Mediated Rejection

NCT05452317
View directory record Official record
Conditions
Antibody-mediated Rejection in Kidney Transplant
Interventions
Chronic active AMR group, Non-Chronic active AMR group
Other
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
3
States / cities
Los Angeles, California • Baltimore, Maryland • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Sep 30, 2026, 7:23 PM EDT
Completed Phase 2 Interventional Results available

A Randomized Controlled Clinical Trial of Thymoglobulin® After Liver Transplantation

NCT02544113
View directory record Official record
Conditions
Liver Failure
Interventions
Thymoglobulin, Placebo
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
4
States / cities
Weston, Florida • Cincinnati, Ohio • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Sep 30, 2026, 7:23 PM EDT